Literature DB >> 9810441

Gliomatosis cerebri: clinical features, treatment, and prognosis.

D G Kim1, H J Yang, I A Park, J G Chi, H W Jung, D H Han, K S Choi, B K Cho.   

Abstract

To clarify clinical features and to elucidate prognostic factors and prognosis, the authors retrospectively analyzed 16 cases of gliomatosis cerebri treated at Seoul National University Hospital between January 1988 and December 1995. Age at diagnosis ranged from 19 to 62 (median 34) years and male to female ratio was 10:6. Most presented with headache or seizure, and the mean duration of symptoms was 12.8 months. A poorly defined diffuse high signal intensity lesion, extending in T2-weighted images for two lobes or more, was the characteristic magnetic resonance (MR) image finding. On postcontrast T1-weighted MR imaging, focal enhancement of the lesion was detected in five cases. All patients underwent histological confirmation by craniotomy (9 cases) or stereotactic biopsy (7 cases). Histologically, all patients had compatible findings of gliomatosis cerebri which are the widespread infiltration of neoplastic glial cells with minimal destruction of pre-existing structures. After histological diagnosis, external radiation therapy was begun except in one case, who declined this treatment. Fourteen patients completed the whole procedure and received the planned dose (mean 5780 cGy). Median survival time after diagnosis was 38.4 months. In univariate analysis, the Ki-67 labelling index (> 1) showed significant correlation with the length of survival (p = 0.006). It is suggested that 1) gliomatosis cerebri can be diagnosed by a combination of MR imaging findings and histological examination; 2) histological diagnosis and external radiation therapy might be a good treatment modality; 3) the Ki-67 labelling index correlates significantly with survival time.

Entities:  

Mesh:

Year:  1998        PMID: 9810441     DOI: 10.1007/s007010050176

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  23 in total

1.  Progressive dementia and gait disorder in a 78 year old woman.

Authors:  M Tagliati; D P Perl; B Drayer; C W Olanow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

2.  Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide.

Authors:  C Mawrin; V Aumann; E Kirches; R Schneider-Stock; C Scherlach; S Vogel; U Mittler; K Dietzmann; G Krause; S Weis
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

3.  Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature.

Authors:  Sophie Taillibert; Catherine Chodkiewicz; Florence Laigle-Donadey; Massimo Napolitano; Stéphanie Cartalat-Carel; Marc Sanson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

4.  An uncommon cause of transient neurological dysfunction.

Authors:  Muhammad U Farooq; Archit Bhatt; Howard T Chang
Journal:  Neurohospitalist       Date:  2014-07

5.  Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri.

Authors:  Stanley Yang; Stephan Wetzel; M Law; D Zagzag; Soonmee Cha
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

6.  Exclusive radiotherapy for gliomatosis cerebri: long-term follow-up at a single institution.

Authors:  K Kim; E K Chie; H J Park; D G Kim; H-W Jung; S-H Park; I H Kim
Journal:  Clin Transl Oncol       Date:  2014-01-29       Impact factor: 3.405

7.  Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation.

Authors:  Ivan Fernandez-Vega; Jennifer Quirk; Fiona L Norwood; Naomi A Sibtain; Ross Laxton; Istvan Bodi
Journal:  Pathol Oncol Res       Date:  2013-12-19       Impact factor: 3.201

8.  Histological and MR correlations in Gliomatosis cerebri.

Authors:  Paule Peretti-Viton; Hervé Brunel; Olivier Chinot; Clément Daniel; Maryline Barrié; Corinne Bouvier; Dominique Figarella-Branger; Stéphane Fuentes; Henry Dufour; François Grisoli
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

9.  Impact of adjuvant chemotherapy for gliomatosis cerebri.

Authors:  Doo-Sik Kong; Sung Tae Kim; Jung-Il Lee; Yeon-Lim Suh; Do Hoon Lim; Won Seog Kim; Ki-Hoon Kwon; Kwan Park; Jong Hyun Kim; Do-Hyun Nam
Journal:  BMC Cancer       Date:  2010-08-13       Impact factor: 4.430

10.  Presentation patterns and outcome of gliomatosis cerebri.

Authors:  Gustavo G Rajz; Dvora Nass; Elisa Talianski; Raphael Pfeffer; Roberto Spiegelmann; Zvi R Cohen
Journal:  Oncol Lett       Date:  2011-10-18       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.